New trial
FAST NOVEMBER: A Phase II Randomized Trial of a 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
- Trial ID
- NCT06961955 on ClinicalTrials.gov
- Cancer type
- Breast Cancer
- Published in
- New in Oncology - May 21, 2025
University of Utah is evaluating the optimal duration for whole breast radiotherapy—with both 5- and 9-day schedules using a brachytherapy device—in early-stage adjuvant breast cancer.
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer